Literature DB >> 31987933

Overinhibition mediated by parvalbumin interneurons might contribute to depression-like behavior and working memory impairment induced by lipopolysaccharide challenge.

Mu-Huo Ji1, Ling Zhang2, Ming-Jie Mao3, Hui Zhang2, Jiao-Jiao Yang2, Li-Li Qiu4.   

Abstract

Systemic inflammation induces cognitive impairments via unclear mechanisms. Accumulating evidence has demonstrated that a subset of neurons that express parvalbumin (PV) play a critical role in regulation of cognitive and emotional behavior. Thus, the aim of the present study was to test whether disruption of PV interneuron mediates systemic inflammation-induced depression-like behavior and working memory impairment by lipopolysaccharide (LPS) challenge. Here we showed that LPS induces depression-like behavior and working memory impairment, coinciding with increased PV expression, enhanced GABAergic transmission, and impaired long-term potentiation (LTP) in the hippocampus. Notably, systemic administration of NMDA (N-methyl-D-aspartate) receptor (NMDAR) antagonist ketamine was able to interfere with PV expression and reverse depression-like behavior and working memory impairment, which is probably mediated by reversing impaired LTP. In addition, flumazenil, a competitive antagonist acting at the benzodiazepine binding site of the GABAA receptor, also ameliorated these abnormal behaviors. Collectively, our study added growing evidence to the limited studies that overinhibition mediated by PV interneurons might play a critical role in LPS-induced depression-like behavior and working memory impairment.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Depression-Like behavior; GABA; Parvalbumin; Sepsis; Working memory

Mesh:

Substances:

Year:  2020        PMID: 31987933     DOI: 10.1016/j.bbr.2020.112509

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  7 in total

1.  Neuroprotective effect of mildronate and L-carnitine on the cognitive parameters of aged mice and mice with LPS-induced inflammation.

Authors:  Ekaterina A Shaforostova; Artem P Gureev; Daria E Volodina; Vasily N Popov
Journal:  Metab Brain Dis       Date:  2022-07-26       Impact factor: 3.655

Review 2.  Current Understanding of Long-Term Cognitive Impairment After Sepsis.

Authors:  Ying Li; Muhuo Ji; Jianjun Yang
Journal:  Front Immunol       Date:  2022-05-06       Impact factor: 8.786

Review 3.  Brain NMDA Receptors in Schizophrenia and Depression.

Authors:  Albert Adell
Journal:  Biomolecules       Date:  2020-06-23

Review 4.  Sepsis-Induced Brain Dysfunction: Pathogenesis, Diagnosis, and Treatment.

Authors:  Shangwen Pan; Zheng Lv; Rui Wang; Huaqing Shu; Shiying Yuan; Yuan Yu; You Shang
Journal:  Oxid Med Cell Longev       Date:  2022-08-24       Impact factor: 7.310

Review 5.  Candidate Strategies for Development of a Rapid-Acting Antidepressant Class That Does Not Result in Neuropsychiatric Adverse Effects: Prevention of Ketamine-Induced Neuropsychiatric Adverse Reactions.

Authors:  Motohiro Okada; Yasuhiro Kawano; Kouji Fukuyama; Eishi Motomura; Takashi Shiroyama
Journal:  Int J Mol Sci       Date:  2020-10-26       Impact factor: 5.923

6.  The Dual Role of the GABAA Receptor in Peripheral Inflammation and Neuroinflammation: A Study in Hyperammonemic Rats.

Authors:  Michele Malaguarnera; Tiziano Balzano; Mari Carmen Castro; Marta Llansola; Vicente Felipo
Journal:  Int J Mol Sci       Date:  2021-06-24       Impact factor: 5.923

7.  Modulation of behavioral and neurochemical responses of adult zebrafish by fluoxetine, eicosapentaenoic acid and lipopolysaccharide in the prolonged chronic unpredictable stress model.

Authors:  Konstantin A Demin; Tatiana O Kolesnikova; David S Galstyan; Nataliya A Krotova; Nikita P Ilyin; Ksenia A Derzhavina; Nataliia A Levchenko; Tatyana Strekalova; Murilo S de Abreu; Elena V Petersen; Maria Seredinskaya; Yulia V Cherneyko; Yuriy M Kositsyn; Dmitry V Sorokin; Konstantin N Zabegalov; Mikael S Mor; Evgeniya V Efimova; Allan V Kalueff
Journal:  Sci Rep       Date:  2021-07-12       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.